Philip Meade

Mr. Philip Meade


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
AWAnia Wajnberg
Ania Wajnberg
FAFatima Amanat
Fatima Amanat
AFAdolfo Firpo-Betancourt
Adolfo Firpo-Betancourt
DADeena R. Altman
Deena R. Altman
MBMark J. Bailey
Mark J. Bailey
CCCarlos Cordon-Cardo
Carlos Cordon-Cardo
SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Questions regarding the robustness, functionality and longevity of the antibody response to the virus remain unanswered. Here we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust IgG antibody responses against the viral spike protein, based on a dataset of 19,860 individuals screened at Mount Sinai Health System in New York City. We also show that titers are stable for at least a period approximating three months, and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggests that more than 90% of seroconverters make detectible neutralizing antibody responses and that these titers are stable for at least the near-term future. One Sentence Summary: Antibody responses induced by natural mild-to-moderate SARS-CoV-2 infection are robust, neutralizing and are stable for at least 3 months.

14 September 2018 in Vaccines
Verified
Journal Article
Open access
PDF file
SSSun Young Sunwoo
Sun Young Sunwoo
MSMichael Schotsaert
Michael Schotsaert
IMIgor Morozov
Igor Morozov
Anne Sally DavisAnne Sally Davis
Anne Sally Davis
YLYuhao Li
Yuhao Li
JRJuergen A. Richt
Juergen A. Richt
The antigenically conserved hemagglutinin stalk region is a target for universal influenza virus vaccines since antibodies against it can provide broad protection against influenza viruses of different subtypes. We tested a universal influenza virus vaccination regimen based on sequential immunization with chimeric hemagglutinin (HA) containing viruses in a swine influenza virus pig model with maternal antibodies against pandemic H1N1. Vaccines were administered as live attenuated virus or inactivated influenza virus split vaccine (+/− Emulsigen adjuvant). As controls, we included groups that received trivalent inactivated influenza vaccine that contained pandemic H1N1 antigens, inactivated adjuvanted H1N2 vaccine (control group for vaccine associated enhanced respiratory disease in the pig model) or mock-vaccination. No induction of H1 head or stalk-specific antibody responses was observed upon vaccination, while responses against H3 and influenza B HA were elicited in the group vaccinated with the trivalent vaccine. Four weeks post vaccination, pigs were intratracheally challenged with pandemic H1N1 virus and euthanized 5 days after challenge. Despite the lack of detectable anti-stalk immunity, the chimeric hemagglutinin vaccine resulted in better clinical outcomes compared to control groups.

27 November 2018 in Vaccines
Verified
Journal Article
Open access
PDF file
SSSun Young Sunwoo
Sun Young Sunwoo
MSMichael Schotsaert
Michael Schotsaert
IMIgor Morozov
Igor Morozov
Anne Sally DavisAnne Sally Davis
Anne Sally Davis
YLYuhao Li
Yuhao Li
JRJuergen A. Richt
Juergen A. Richt
In the published article, “A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies.